Batiraxcept

Phase 3Protein / enzyme

AAravive, Inc.

Batiraxcept is one of 138 small molecule programs targeting Uterine Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

137

Competitors

Pipeline

Status by Indication[3][1]

Indication

Uterine CancerActive, not recruiting

Pancreatic AdenocarcinomaActive, not recruiting

Ovarian CancerActive, not recruiting

Renal Cell CarcinomaActive, not recruiting

Uterine CancerPhase 1

Active, not recruiting

Pancreatic AdenocarcinomaPhase 1/Phase 2

Active, not recruiting

Ovarian CancerPhase 3

Active, not recruiting

Renal Cell CarcinomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

836 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Hycamtin

MMeitheal

Phase 3

28 2

Femara

Novartis

Phase 3

10 3

Imfinzi

AstraZeneca

Phase 3

8 4

Votrient

Novartis

Phase 3

8 5

Perjeta

Roche

Phase 3

3 6

Bavencio

EMD Serono

Phase 3

7 7

Neupogen

EEastern Cooperative Oncology Group

Phase 3

6 8

IV Iron

Pfizer

Phase 3

1 9

Batiraxcept

AAravive, Inc.

Phase 3

1 10

VB-111

VVascular Biogenics Ltd. operating as VBL Therapeutics

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ovarian Cancer1 trial

Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Terminated·AAravive, Inc.·Phase 3·NCT04729608·366 enrolled

Pancreatic Adenocarcinoma1 trial

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma

Terminated·AAravive, Inc.·Phase 1/2·NCT04983407·34 enrolled

Primary Peritoneal Cancer1 trial

AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT04019288·12 enrolled

Renal Cell Carcinoma1 trial

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Terminated·AAravive, Inc.·Phase 1/2·NCT04300140·72 enrolled

Uterine Cancer1 trial

AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

Withdrawn·WWashington University School of Medicine·Phase 1·NCT05826015

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Batiraxcept. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Batiraxcept compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Batiraxcept. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aravive, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 3[1]
Company: AAravive, Inc.

Batiraxcept

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ovarian Cancer1 trial

Pancreatic Adenocarcinoma1 trial

Primary Peritoneal Cancer1 trial

Renal Cell Carcinoma1 trial

Uterine Cancer1 trial

References

Drug Info

Quick Facts

Related News